Fig. 45.1 Model of target cells and involved factors. Advanced model of target cells and factors involved in the therapeutic modulation of hyperproliferative/fibrotic benign diseases by a low-dose radiation therapy….
Fig. 13.1 Overview network analysis. Simplified workflow of the network analysis integrating GWAS and transcriptome data to search for disease-specific sub-networks in DD. In the first step SNP-based p-values are…
Fig. 4.1 Number of DC diagnoses by quarter Since the approval of CCH in Q1 2010, the use of CCH has steadily increased from 5 % of all DC procedures…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_39 39. Is Recurrence After Treatment Predictable? Risk Factors in Dupuytren Disease…
(Cline 1777) It does not appear that Dupuytren met with any mischief when he did the operation in this way……. . I think it would be altogether impossible to escape suppuration…
Fig. 30.1 Mobile device application measurements of Dupuytren contracture. With the aid of the mobile device application, lines are superimposed of the mid-axes of the affected fingers as judged by…
Fig. 28.1 Use of the tumorimeter. (a) The nodule is encircled, (b) the loop is placed over the nodule, whereafter the surface area can be read off 28.2.3 Procedure All…
Author Lermusiaux et al. (2001) Foucher et al. (2003) Van Rijssen et al. (2006) Pess et al. (2012) Hurst et al. (2009) PNF PNF PNF PNF CCH SAE Tendon…
Fig. 19.1 Risk matrix 19.4.5 Recurrence as an Outcome Measure This poses a particular problem. There is no accepted definition of recurrence. A recurrence may hold different value after different…
Fig. 15.1 Experienced pain during injection and interval. Mean visual analog scale (VAS) scores for pain experienced during the first injection (buffered mepivacaine in the local anesthesia [LA] group; collagenase…
